Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-07-20

AUTHORS

Melanie J. Davies, Divina Glah, Barrie Chubb, Gerasimos Konidaris, Phil McEwan

ABSTRACT

ObjectivesOnce-daily insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon like peptide-1 receptor agonist combined in one delivery device. Our aim was to investigate the cost effectiveness of IDegLira vs. basal insulin intensification therapies for patients with type 2 diabetes mellitus uncontrolled on basal insulin (glycosylated haemoglobin; HbA1c >7.5 %; 58 mmol/mol) in a UK setting.Research Design and MethodsBaseline cohort and clinical parameters were sourced from a pooled analysis comparing IDegLira with basal insulin plus liraglutide and basal-bolus therapy, and from the DUAL™ V trial comparing IDegLira with up-titrated insulin glargine (IGlar; Lantus®). The CORE Diabetes Model simulated lifetime costs and outcomes with IDegLira vs. these comparators from a UK healthcare payers’ perspective. All costs were expressed in 2015 GBP. Sensitivity analyses were performed to assess the impact of key parameters in the model.ResultsTreatment with IDegLira resulted in mean increases in quality-adjusted life-years (QALYs) of 0.12, 0.41 and 0.24 vs. basal insulin plus liraglutide, basal-bolus therapy and up-titrated IGlar, respectively. IDegLira was associated with lower costs of £971 and £1698 vs. basal insulin plus liraglutide and basal-bolus therapy, respectively, and increased costs of £1441 vs. up-titrated IGlar. IDegLira was dominant, i.e., both more effective and less costly vs. basal insulin plus liraglutide and basal-bolus therapy, and highly cost effective vs. up-titrated IGlar with an incremental cost-effectiveness ratio of £6090/QALY gained.ConclusionsOnce-daily IDegLira may be considered a cost-effective treatment option for prescribers, to improve glycaemic control for type 2 diabetes patients uncontrolled on basal insulin without an increased risk of hypoglycaemia or weight gain, and without adding to their injection burden. More... »

PAGES

953-966

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-016-0433-9

DOI

http://dx.doi.org/10.1007/s40273-016-0433-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003778828

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27438706


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycated Hemoglobin A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin, Long-Acting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liraglutide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK", 
          "id": "http://www.grid.ac/institutes/grid.412934.9", 
          "name": [
            "Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davies", 
        "givenName": "Melanie J.", 
        "id": "sg:person.014257756332.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014257756332.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk Ltd, 3 City Place, Beehive Ring Road, RH6 0PA, Gatwick, West Sussex, UK", 
          "id": "http://www.grid.ac/institutes/grid.436696.8", 
          "name": [
            "Novo Nordisk Ltd, 3 City Place, Beehive Ring Road, RH6 0PA, Gatwick, West Sussex, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Glah", 
        "givenName": "Divina", 
        "id": "sg:person.0700332675.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700332675.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk Ltd, 3 City Place, Beehive Ring Road, RH6 0PA, Gatwick, West Sussex, UK", 
          "id": "http://www.grid.ac/institutes/grid.436696.8", 
          "name": [
            "Novo Nordisk Ltd, 3 City Place, Beehive Ring Road, RH6 0PA, Gatwick, West Sussex, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chubb", 
        "givenName": "Barrie", 
        "id": "sg:person.01067301036.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067301036.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IMS Health, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.482783.2", 
          "name": [
            "IMS Health, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Konidaris", 
        "givenName": "Gerasimos", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre for Health Economics, Swansea University, Swansea, Wales, UK", 
          "id": "http://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "Centre for Health Economics, Swansea University, Swansea, Wales, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00125-006-0380-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019984445", 
          "https://doi.org/10.1007/s00125-006-0380-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-015-0142-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048653953", 
          "https://doi.org/10.1007/s13300-015-0142-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-11-90", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013049175", 
          "https://doi.org/10.1186/1477-7525-11-90"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-013-2940-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010988781", 
          "https://doi.org/10.1007/s00125-013-2940-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-07-20", 
    "datePublishedReg": "2016-07-20", 
    "description": "ObjectivesOnce-daily insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon like peptide-1 receptor agonist combined in one delivery device. Our aim was to investigate the cost effectiveness of IDegLira vs. basal insulin intensification therapies for patients with type 2 diabetes mellitus uncontrolled on basal insulin (glycosylated haemoglobin; HbA1c >7.5\u00a0%; 58\u00a0mmol/mol) in a UK setting.Research Design and MethodsBaseline cohort and clinical parameters were sourced from a pooled analysis comparing IDegLira with basal insulin plus liraglutide and basal-bolus therapy, and from the DUAL\u2122 V trial comparing IDegLira with up-titrated insulin glargine (IGlar; Lantus\u00ae). The CORE Diabetes Model simulated lifetime costs and outcomes with IDegLira vs. these comparators from a UK healthcare payers\u2019 perspective. All costs were expressed in 2015 GBP. Sensitivity analyses were performed to assess the impact of key parameters in the model.ResultsTreatment with IDegLira resulted in mean increases in quality-adjusted life-years (QALYs) of 0.12, 0.41 and 0.24 vs. basal insulin plus liraglutide, basal-bolus therapy and up-titrated IGlar, respectively. IDegLira was associated with lower costs of \u00a3971 and \u00a31698 vs. basal insulin plus liraglutide and basal-bolus therapy, respectively, and increased costs of \u00a31441 vs. up-titrated IGlar. IDegLira was dominant, i.e., both more effective and less costly vs. basal insulin plus liraglutide and basal-bolus therapy, and highly cost effective vs. up-titrated IGlar with an incremental cost-effectiveness ratio of \u00a36090/QALY gained.ConclusionsOnce-daily IDegLira may be considered a cost-effective treatment option for prescribers, to improve glycaemic control for type 2 diabetes patients uncontrolled on basal insulin without an increased risk of hypoglycaemia or weight gain, and without adding to their injection burden.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40273-016-0433-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "basal-bolus therapy", 
      "basal insulin", 
      "intensification therapy", 
      "insulin degludec/liraglutide", 
      "type 2 diabetes mellitus", 
      "type 2 diabetes patients", 
      "UK setting", 
      "incremental cost-effectiveness ratio", 
      "cost-effective treatment option", 
      "first basal insulin", 
      "risk of hypoglycaemia", 
      "cost-effectiveness ratio", 
      "injection burden", 
      "Mellitus Uncontrolled", 
      "glycaemic control", 
      "diabetes mellitus", 
      "insulin glargine", 
      "clinical parameters", 
      "pooled analysis", 
      "treatment options", 
      "diabetes patients", 
      "receptor agonist", 
      "IDegLira", 
      "liraglutide", 
      "cost effectiveness", 
      "mean increase", 
      "type 2", 
      "therapy", 
      "IGlar", 
      "insulin", 
      "weight gain", 
      "patients", 
      "healthcare payers", 
      "lifetime costs", 
      "research design", 
      "delivery devices", 
      "mellitus", 
      "glargine", 
      "ResultsTreatment", 
      "hypoglycaemia", 
      "glucagon", 
      "prescribers", 
      "agonists", 
      "cohort", 
      "setting", 
      "QALY", 
      "trials", 
      "outcomes", 
      "risk", 
      "burden", 
      "payers", 
      "uncontrolled", 
      "aim", 
      "options", 
      "control", 
      "effectiveness", 
      "sensitivity analysis", 
      "increase", 
      "comparator", 
      "analysis", 
      "impact", 
      "ratio", 
      "gain", 
      "cost", 
      "model", 
      "parameters", 
      "perspective", 
      "low cost", 
      "design", 
      "devices", 
      "core", 
      "Gbps", 
      "key parameters", 
      "dual", 
      "ObjectivesOnce-daily insulin degludec/liraglutide", 
      "degludec/liraglutide", 
      "basal insulin intensification therapies", 
      "insulin intensification therapies", 
      "MethodsBaseline cohort", 
      "UK healthcare payers", 
      "ConclusionsOnce-daily IDegLira", 
      "Alternative Basal Insulin Intensification Therapies"
    ], 
    "name": "Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting", 
    "pagination": "953-966", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003778828"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-016-0433-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27438706"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-016-0433-9", 
      "https://app.dimensions.ai/details/publication/pub.1003778828"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_693.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40273-016-0433-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0433-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0433-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0433-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-016-0433-9'


 

This table displays all metadata directly associated to this object as RDF triples.

252 TRIPLES      22 PREDICATES      126 URIs      114 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-016-0433-9 schema:about N019c1c3125164327b381d054a5bed68d
2 N109a2cf3f77b422485c7bf46a285ff13
3 N223277df50054de08e137ccbd8a2ff2b
4 N3fc5cf66b77841a586810679bc689a10
5 N5340afaee64c4970a4c8f0cd6b4a6fde
6 N57b24ea6201f48b3a383ed23fbdbec3d
7 N62220a1bf888497e99df28cdf77b57ba
8 N86f0b0bc8b7646f78733c18bce51eee2
9 N89a5358764c041428cb66d23714b28be
10 N91af850a7a9347328516e3fbb968cecd
11 Nb590eb59e86d4a0980ee7b31752d71fe
12 Nb81d621ea38e4107b2b6e050a4cddf07
13 Ndf9e5d24053f4b5f92fb276e99b29bd0
14 Nec20b32e1cfc48bdb40e7c6c1c023117
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nc7ea206e30db42ac857700245bc74152
18 schema:citation sg:pub.10.1007/s00125-006-0380-7
19 sg:pub.10.1007/s00125-013-2940-y
20 sg:pub.10.1007/s13300-015-0142-y
21 sg:pub.10.1186/1477-7525-11-90
22 schema:datePublished 2016-07-20
23 schema:datePublishedReg 2016-07-20
24 schema:description ObjectivesOnce-daily insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon like peptide-1 receptor agonist combined in one delivery device. Our aim was to investigate the cost effectiveness of IDegLira vs. basal insulin intensification therapies for patients with type 2 diabetes mellitus uncontrolled on basal insulin (glycosylated haemoglobin; HbA1c >7.5 %; 58 mmol/mol) in a UK setting.Research Design and MethodsBaseline cohort and clinical parameters were sourced from a pooled analysis comparing IDegLira with basal insulin plus liraglutide and basal-bolus therapy, and from the DUAL™ V trial comparing IDegLira with up-titrated insulin glargine (IGlar; Lantus®). The CORE Diabetes Model simulated lifetime costs and outcomes with IDegLira vs. these comparators from a UK healthcare payers’ perspective. All costs were expressed in 2015 GBP. Sensitivity analyses were performed to assess the impact of key parameters in the model.ResultsTreatment with IDegLira resulted in mean increases in quality-adjusted life-years (QALYs) of 0.12, 0.41 and 0.24 vs. basal insulin plus liraglutide, basal-bolus therapy and up-titrated IGlar, respectively. IDegLira was associated with lower costs of £971 and £1698 vs. basal insulin plus liraglutide and basal-bolus therapy, respectively, and increased costs of £1441 vs. up-titrated IGlar. IDegLira was dominant, i.e., both more effective and less costly vs. basal insulin plus liraglutide and basal-bolus therapy, and highly cost effective vs. up-titrated IGlar with an incremental cost-effectiveness ratio of £6090/QALY gained.ConclusionsOnce-daily IDegLira may be considered a cost-effective treatment option for prescribers, to improve glycaemic control for type 2 diabetes patients uncontrolled on basal insulin without an increased risk of hypoglycaemia or weight gain, and without adding to their injection burden.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf Nbc859fbae4a84fa4bd5c58c495344ace
29 Nd038eb8ecae14e18b5214a34de0d7bcf
30 sg:journal.1102812
31 schema:keywords Alternative Basal Insulin Intensification Therapies
32 ConclusionsOnce-daily IDegLira
33 Gbps
34 IDegLira
35 IGlar
36 Mellitus Uncontrolled
37 MethodsBaseline cohort
38 ObjectivesOnce-daily insulin degludec/liraglutide
39 QALY
40 ResultsTreatment
41 UK healthcare payers
42 UK setting
43 agonists
44 aim
45 analysis
46 basal insulin
47 basal insulin intensification therapies
48 basal-bolus therapy
49 burden
50 clinical parameters
51 cohort
52 comparator
53 control
54 core
55 cost
56 cost effectiveness
57 cost-effective treatment option
58 cost-effectiveness ratio
59 degludec/liraglutide
60 delivery devices
61 design
62 devices
63 diabetes mellitus
64 diabetes patients
65 dual
66 effectiveness
67 first basal insulin
68 gain
69 glargine
70 glucagon
71 glycaemic control
72 healthcare payers
73 hypoglycaemia
74 impact
75 increase
76 incremental cost-effectiveness ratio
77 injection burden
78 insulin
79 insulin degludec/liraglutide
80 insulin glargine
81 insulin intensification therapies
82 intensification therapy
83 key parameters
84 lifetime costs
85 liraglutide
86 low cost
87 mean increase
88 mellitus
89 model
90 options
91 outcomes
92 parameters
93 patients
94 payers
95 perspective
96 pooled analysis
97 prescribers
98 ratio
99 receptor agonist
100 research design
101 risk
102 risk of hypoglycaemia
103 sensitivity analysis
104 setting
105 therapy
106 treatment options
107 trials
108 type 2
109 type 2 diabetes mellitus
110 type 2 diabetes patients
111 uncontrolled
112 weight gain
113 schema:name Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
114 schema:pagination 953-966
115 schema:productId N12b140978cbe4245ab89a61bbdf4c4a4
116 N1cd5120b5d5241faa37b5fde75808d2b
117 Nff5920a71f6842e7a83cb70e4e2e75d5
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003778828
119 https://doi.org/10.1007/s40273-016-0433-9
120 schema:sdDatePublished 2021-11-01T18:27
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N7f97b1ef0f094d738ecf70cf155201c3
123 schema:url https://doi.org/10.1007/s40273-016-0433-9
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N019c1c3125164327b381d054a5bed68d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Hypoglycemia
129 rdf:type schema:DefinedTerm
130 N109a2cf3f77b422485c7bf46a285ff13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Glycated Hemoglobin A
132 rdf:type schema:DefinedTerm
133 N12b140978cbe4245ab89a61bbdf4c4a4 schema:name dimensions_id
134 schema:value pub.1003778828
135 rdf:type schema:PropertyValue
136 N1cd5120b5d5241faa37b5fde75808d2b schema:name doi
137 schema:value 10.1007/s40273-016-0433-9
138 rdf:type schema:PropertyValue
139 N223277df50054de08e137ccbd8a2ff2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Diabetes Mellitus, Type 2
141 rdf:type schema:DefinedTerm
142 N34b00ce2056b4bc9a5289b25c03e9968 rdf:first sg:person.0700332675.01
143 rdf:rest N972613f5268342968d73c01dd796c547
144 N3fc5cf66b77841a586810679bc689a10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Quality-Adjusted Life Years
146 rdf:type schema:DefinedTerm
147 N5340afaee64c4970a4c8f0cd6b4a6fde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Insulins
149 rdf:type schema:DefinedTerm
150 N57b24ea6201f48b3a383ed23fbdbec3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Insulin, Long-Acting
152 rdf:type schema:DefinedTerm
153 N62220a1bf888497e99df28cdf77b57ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Liraglutide
155 rdf:type schema:DefinedTerm
156 N7f97b1ef0f094d738ecf70cf155201c3 schema:name Springer Nature - SN SciGraph project
157 rdf:type schema:Organization
158 N86f0b0bc8b7646f78733c18bce51eee2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name United Kingdom
160 rdf:type schema:DefinedTerm
161 N89a5358764c041428cb66d23714b28be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Drug Combinations
163 rdf:type schema:DefinedTerm
164 N91af850a7a9347328516e3fbb968cecd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Cost-Benefit Analysis
166 rdf:type schema:DefinedTerm
167 N972613f5268342968d73c01dd796c547 rdf:first sg:person.01067301036.89
168 rdf:rest Nb221e6628d704c99ad0fd36edc1ee34a
169 Nb221e6628d704c99ad0fd36edc1ee34a rdf:first Ne56fcd2bcc5c4dffa5b5b3936059c290
170 rdf:rest Nfce3d5be4d3f4ae68b5d1f7187214082
171 Nb590eb59e86d4a0980ee7b31752d71fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Models, Economic
173 rdf:type schema:DefinedTerm
174 Nb81d621ea38e4107b2b6e050a4cddf07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Nbc859fbae4a84fa4bd5c58c495344ace schema:volumeNumber 34
178 rdf:type schema:PublicationVolume
179 Nc7ea206e30db42ac857700245bc74152 rdf:first sg:person.014257756332.18
180 rdf:rest N34b00ce2056b4bc9a5289b25c03e9968
181 Nd038eb8ecae14e18b5214a34de0d7bcf schema:issueNumber 9
182 rdf:type schema:PublicationIssue
183 Ndf9e5d24053f4b5f92fb276e99b29bd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Hypoglycemic Agents
185 rdf:type schema:DefinedTerm
186 Ne56fcd2bcc5c4dffa5b5b3936059c290 schema:affiliation grid-institutes:grid.482783.2
187 schema:familyName Konidaris
188 schema:givenName Gerasimos
189 rdf:type schema:Person
190 Nec20b32e1cfc48bdb40e7c6c1c023117 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Blood Glucose
192 rdf:type schema:DefinedTerm
193 Nfce3d5be4d3f4ae68b5d1f7187214082 rdf:first sg:person.01346767345.38
194 rdf:rest rdf:nil
195 Nff5920a71f6842e7a83cb70e4e2e75d5 schema:name pubmed_id
196 schema:value 27438706
197 rdf:type schema:PropertyValue
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
202 schema:name Clinical Sciences
203 rdf:type schema:DefinedTerm
204 sg:journal.1102812 schema:issn 1170-7690
205 1179-2027
206 schema:name PharmacoEconomics
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01067301036.89 schema:affiliation grid-institutes:grid.436696.8
210 schema:familyName Chubb
211 schema:givenName Barrie
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067301036.89
213 rdf:type schema:Person
214 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.4827.9
215 schema:familyName McEwan
216 schema:givenName Phil
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
218 rdf:type schema:Person
219 sg:person.014257756332.18 schema:affiliation grid-institutes:grid.412934.9
220 schema:familyName Davies
221 schema:givenName Melanie J.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014257756332.18
223 rdf:type schema:Person
224 sg:person.0700332675.01 schema:affiliation grid-institutes:grid.436696.8
225 schema:familyName Glah
226 schema:givenName Divina
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700332675.01
228 rdf:type schema:Person
229 sg:pub.10.1007/s00125-006-0380-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019984445
230 https://doi.org/10.1007/s00125-006-0380-7
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/s00125-013-2940-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010988781
233 https://doi.org/10.1007/s00125-013-2940-y
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s13300-015-0142-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1048653953
236 https://doi.org/10.1007/s13300-015-0142-y
237 rdf:type schema:CreativeWork
238 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
239 https://doi.org/10.1186/1477-7525-11-90
240 rdf:type schema:CreativeWork
241 grid-institutes:grid.412934.9 schema:alternateName Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK
242 schema:name Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK
243 rdf:type schema:Organization
244 grid-institutes:grid.436696.8 schema:alternateName Novo Nordisk Ltd, 3 City Place, Beehive Ring Road, RH6 0PA, Gatwick, West Sussex, UK
245 schema:name Novo Nordisk Ltd, 3 City Place, Beehive Ring Road, RH6 0PA, Gatwick, West Sussex, UK
246 rdf:type schema:Organization
247 grid-institutes:grid.4827.9 schema:alternateName Centre for Health Economics, Swansea University, Swansea, Wales, UK
248 schema:name Centre for Health Economics, Swansea University, Swansea, Wales, UK
249 rdf:type schema:Organization
250 grid-institutes:grid.482783.2 schema:alternateName IMS Health, London, UK
251 schema:name IMS Health, London, UK
252 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...